Back to top
more

OPKO Health (OPK)

(Delayed Data from NSDQ)

$1.45 USD

1.45
1,271,977

-0.05 (-3.33%)

Updated Oct 27, 2025 04:00 PM ET

After-Market: $1.44 -0.01 (-0.69%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.16%
3Hold10.10%
4Sell5.63%
5Strong Sell2.84%
S&P50011.45%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (89 out of 243)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Opko Health (OPK) Rallies on Q1 Earnings and Revenue Beat

by Zacks Equity Research

Opko Health (OPK) gains from solid pharmaceutical business in the first quarter of 2018.

    Zacks Equity Research

    Implied Volatility Surging for Opko Health (OPK) Stock Options

    by Zacks Equity Research

    Surging implied volatility makes Opko Health (OPK) lucrative to the option traders.

      Zacks Equity Research

      OPKO Health (OPK) Q4 Earnings Decline Y/Y, Margins Down

      by Zacks Equity Research

      OPKO Health (OPK) posts lackluster Q4 numbers due to rising operating expenses owing to investments associated with the launch of RAYALDEE and consistent investments in the pharmaceutical pipeline.

        Zacks Equity Research

        Why OPKO Health (OPK) Could Be Positioned for a Slump

        by Zacks Equity Research

        OPKO Health (OPK) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.

          Zacks Equity Research

          4 Medical Device Stocks to Top Q3 Earnings

          by Zacks Equity Research

          A look at how medical device players are poised for this earnings season.

            Zacks Equity Research

            OPKO Health (OPK) Signs New Agreement with Japan Tobacco

            by Zacks Equity Research

            OPKO Health's (OPK) new agreement with Japan Tobacco will enhance prospects of its kidney drug RAYALDEE in Japan.

              Zacks Equity Research

              Is the Options Market Predicting a Spike in Opko Health (OPK) Stock?

              by Zacks Equity Research

              Investors in Opko Health (OPK) need to pay close attention to the stock based on moves in the options market lately.

                Zacks Equity Research

                OPKO Health (OPK) Posts Narrower-than-Estimated Loss in Q2

                by Zacks Equity Research

                OPKO Health (OPK) posted lackluster Q2 numbers due to rising operating expenses owing to investment associated to the launch of RAYALDEE, and consistent investment in the pharmaceutical pipeline.

                  Zacks Equity Research

                  Med-Product Stocks Aug 8 Earnings Roster: HSIC, AGIO & More

                  by Zacks Equity Research

                  Long-term tailwinds including M&A, emerging markets, positive demographic trends and new product innovation might bode well for the medical device industry.

                    Zacks Equity Research

                    Is the Options Market Predicting a Spike in Opko Health (OPK) Stock?

                    by Zacks Equity Research

                    Surging level of implied volatility makes Opko Health (OPK) Stock lucrative to the option traders.

                      Zacks Equity Research

                      Medical Product Q1 Earnings on May 8: ITGR, OPK & More

                      by Zacks Equity Research

                      Let's take a look at the major Medical products stocks slated to release their first-quarter 2017 reports on May 8.

                        Zacks Equity Research

                        OPKO Health (OPK) Launches Prenatal Testing Tool ClariTest

                        by Zacks Equity Research

                        OPKO Health Inc. (OPK) recently announced the launch of a non-invasive medical test to detect fetal abnormalities.

                          Arpita Dutt headshot

                          Biotech Stock Roundup: Inotek Plunges on Pipeline Setback, Kite Files IND for Study Initiation

                          by Arpita Dutt

                          Although this was a relatively slow week for the biotech sector, Inotek (ITEK) made it to the headlines on disappointing data on its lead pipeline drug.

                            Zacks Equity Research

                            OPKO Health (OPK) Reports Failure in hGH-CTP Phase 3

                            by Zacks Equity Research

                            OPKO Health Inc. (OPK) announced failure in its data analysis of the Phase 3 Clinical Study of hGH-CTP in Growth Hormone Deficient Adults.

                              Zacks Equity Research

                              4 Medical Device Stocks on a Bull Run this Earnings Season

                              by Zacks Equity Research

                              The expected positive third-quarter performance by the broader Medical sector is something investors definitely need to muse on.